WAKEFIELD, Mass.–(BUSINESS WIRE)– #anywherelightgoes–Optikos is excited to announce the release of their ColliMeter™ measurement system for the precise setup and qualification of collimators.
Author: Business Wire
Fabrinet Publishes 2023 Sustainability Report
BANGKOK, Thailand–(BUSINESS WIRE)–Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today pub…
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, and SharpeVision, a premier…
DigitalOptometrics Revolutionizes Eye Care by Launching “DOT” (DigitalOptometrics Translate). Now, you can speak your patients' language with DigitalOptometrics Translate
LAKE SUCCESS, N.Y.–(BUSINESS WIRE)– #digitaloptometrics–DigitalOptometrics, a leader in telehealth solutions for eye care, announces the unveiling of “DOT,” a groundbreaking translation service.
National Stem Cell Foundation Travels with Axiom Space Mission to Continue Innovative Neurodegeneration Research on the International Space Station
LOUISVILLE, Ky.–(BUSINESS WIRE)– #ISS–NSCF’s Cosmic Brain Organoid project is a study of neurodegeneration on the ISS, derived from the cells of people with Parkinson’s and MS.
Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8
NEWTON, Mass.–(BUSINESS WIRE)– #NRTIs–Inflammasome Therapeutics announces first patient dosed in Phase 1 DME study of novel dual inflammasome inhibitor K8 to treat inflammation causing DME
Chemify Partners with Prepaire Labs to Apply Ground-breaking Chemistry AI-Robotics to Radically Accelerate the Discovery of Non-Addictive Opioids
GLASGOW, Scotland & PITTSFIELD, Mass.–(BUSINESS WIRE)– #Chemify–Chemify and Prepaire™ Labs announced will tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids.
NVISION Continues Expansion in Texas with Parkhurst NuVision Joint Venture
ALISO VIEJO, Calif.–(BUSINESS WIRE)–NVISION Eye Centers, a national leader in eye care services, is proud to announce its continued expansion in Texas with a new Joint Venture partnership with Parkhurst NuVision in San Antonio and New Braunfels. Park…
Pair Eyewear Launches Collaboration with Leading Optical Retailer National Vision
DULUTH, Ga. & NEW YORK–(BUSINESS WIRE)–Pair Eyewear, the direct-to-consumer customizable eyewear brand reimagining the eyewear industry, announced a new partnership with National Vision, Inc. (NASDAQ: EYE), the second largest optical retailer in Amer…
ERS Genomics and StemSight Sign CRISPR/Cas9 License Agreement
DUBLIN, Ireland & TAMPERE, Finland–(BUSINESS WIRE)–ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and S…
LumiThera kondigt start aan van EUROLIGHT-registeronderzoek om langetermijnvoordelen van fotobiomodulatie (PBM)-behandeling met behulp van het Valeda® Light Delivery System te evalueren bij patiënten met droge leeftijdsgebonden maculaire…
SEATTLE–(BUSINESS WIRE)– LumiThera kondigt start aan van EUROLIGHT-registeronderzoek om langetermijnvoordelen van fotobiomodulatie (PBM)-behandeling met behulp van het Valeda® Light Delivery System te evalueren bij patiënten met droge leeftijdsgebon…
LumiThera kündigt den Beginn der EUROLIGHT-Registerstudie an, um die langfristigen Vorteile der Photobiomodulationsbehandlung (PBM) mit dem Valeda® Light Delivery System bei Patienten mit trockener altersbedingter Makuladegeneration (AMD) zu…
SEATTLE–(BUSINESS WIRE)– LumiThera kündigt den Beginn der EUROLIGHT-Registerstudie an, um die langfristigen Vorteile der Photobiomodulationsbehandlung (PBM) mit dem Valeda® Light Delivery System bei Patienten mit trockener altersbedingter Makuladege…
LumiThera annuncia l'avvio dello studio di registro EUROLIGHT per valutare i vantaggi sul lungo termine del trattamento con fotobiomodulazione (PBM) con Valeda® Light Delivery System nei pazienti con degenerazione maculare senile (DMS) secca
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., un’azienda produttrice di dispositivi medici che offre trattamenti di fotobiomodulazione (PBM) per i danni e le malattie oculari, ha annunciato oggi l’avvio del più grande studio di PBM mai condotto su pazienti…
LumiThera annonce le lancement de l'étude de registre EUROLIGHT pour l'évaluation des avantages à long terme du traitement par Photobiomodulation (PBM) à l'aide du ®Système d'émission de lumière Valeda chez les patients atteints de dégénérescence…
SEATTLE–(BUSINESS WIRE)– LumiThera annonce le lancement de l’étude de registre EUROLIGHT pour l’évaluation des avantages à long terme du traitement par Photobiomodulation (PBM) à l’aide du ®Système d’émission de lumière Valeda chez les patients atte…
Samenvatting: Aviceda Therapeutics kondigt topline-gegevens aan van Deel 1 van de klinische proef Fase 2/3 SIGLEC voor AVD-104, die positieve veiligheid en vroege klinische efficiëntie aantoont bij patiënten met geografische atrofie
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, een biotechnologiebedrijf in klinische fase dat zich toelegt op het ontwikkelen van nieuwe glyco-immune therapeutische middelen door het natuurlijke immuunsysteem van het lichaam te benutten om o…
Aviceda Therapeutics annonce les résultats préliminaires de la première partie de l’essai clinique SIGLEC de Phase 2/3 concernant AVD-104, qui démontrent une sécurité positive et une efficacité clinique précoce chez des patients…
CAMBRIDGE, Massachusetts–(BUSINESS WIRE)– Aviceda Therapeutics annonce les résultats préliminaires de la première partie de l’essai clinique SIGLEC de Phase 2/3 concernant AVD-104, qui démontrent une sécurité positive et une efficacité clinique préc…
LumiThera anuncia el inicio del estudio de registro EUROLIGHT para evaluar los beneficios a largo plazo del tratamiento de fotobiomodulación (PBM, por sus siglas en inglés) utilizando el Valeda® Light Delivery System en pacientes con degeneración…
SEATTLE–(BUSINESS WIRE)– LumiThera anuncia el inicio del estudio de registro EUROLIGHT para evaluar los beneficios a largo plazo del tratamiento de fotobiomodulación (PBM, por sus siglas en inglés) utilizando el Valeda® Light Delivery System en paci…
Aviceda Therapeutics gibt Topline-Daten von Teil 1 der klinischen Phase-2/3-SIGLEC-Studie für AVD-104 bekannt, die eine positive Sicherheitsbewertung und eine frühe klinische Wirksamkeit bei Patienten mit geografischer Atrophie belegen
CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Aviceda Therapeutics, ein im klinischen Stadium tätiges Biotech-Unternehmen, dessen Schwerpunkt auf der Entwicklung neuartiger Glyko-Immuntherapeutika liegt, die das körpereigene Immunsystem zur Modulation von…
Riassunto: Aviceda Therapeutics annuncia i dati di punta dalla Prima parte dello studio clinico di fase 2/3 SIGLEC per AVD-104, dimostrando la sicurezza positiva e l'efficacia clinica precoce nei pazienti affetti da atrofia geografica
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, società biotecnologica allo stadio clinico incentrata sullo sviluppo di nuovi farmaci gluco-immunitari utilizzando il sistema immunitario naturale dell’organismo per modulare l’infiammazione graz…
Resumen: Aviceda Therapeutics anuncia los datos generales de la primera parte de la fase 2/3 del ensayo clínico SIGLEC para AVD-104, que revela resultados positivos en cuanto a seguridad y eficacia clínica temprana en pacientes con atrofia geográfica
CAMBRIDGE (Massachusetts, EE. UU.)–(BUSINESS WIRE)–Aviceda Therapeutics, empresa privada de biotecnología especializada en el desarrollo de nuevas terapias glicoinmunes mediante el aprovechamiento del sistema inmunitario natural del cuerpo para regul…